These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92. Decoding γδ T cell anticancer therapies: integrating CRISPR screens with tumor organoids. Zhou J; Wu M; Yang G Signal Transduct Target Ther; 2023 Nov; 8(1):423. PubMed ID: 37953309 [No Abstract] [Full Text] [Related]
93. Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Kwan A; Winder N; Atkinson E; Al-Janabi H; Allen RJ; Hughes R; Moamin M; Louie R; Evans D; Hutchinson M; Capper D; Cox K; Handley J; Wilshaw A; Kim T; Tazzyman SJ; Srivastava S; Ottewell P; Vadakekolathu J; Pockley G; Lewis CE; Brown JE; Danson SJ; Conner J; Muthana M Mol Cancer Ther; 2021 Mar; 20(3):589-601. PubMed ID: 33298589 [TBL] [Abstract][Full Text] [Related]
94. Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Burman B; Pesci G; Zamarin D Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260685 [TBL] [Abstract][Full Text] [Related]
95. Re: "Oncolytic Measles Virus Encoding Interleukin-12 Mediated Antitumor Activity and Immunologic Control of Colon Cancer Engeland CE Cancer Biother Radiopharm; 2021 Feb; 36(1):106-107. PubMed ID: 33259718 [No Abstract] [Full Text] [Related]
96. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? Zhang S; Rabkin SD Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188 [No Abstract] [Full Text] [Related]
97. Oncolytic Viruses in the Era of Omics, Computational Technologies, and Modeling: Thesis, Antithesis, and Synthesis. Menotti L; Vannini A Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139207 [TBL] [Abstract][Full Text] [Related]
98. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical. Tang C; Li L; Mo T; Na J; Qian Z; Fan D; Sun X; Yao M; Pan L; Huang Y; Zhong L Clin Transl Oncol; 2022 Sep; 24(9):1682-1701. PubMed ID: 35612653 [TBL] [Abstract][Full Text] [Related]
99. Gene Editing Thumbs a Ride with Oncolytic Virotherapy. Wang PY; Cripe TP Mol Ther; 2020 Oct; 28(10):2103-2104. PubMed ID: 32966770 [No Abstract] [Full Text] [Related]
100. CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]